Table 2 Clinical-stage nanomedicines to boost Treg cells
From: Harnessing the biology of regulatory T cells to treat disease
Lead company | Nanoparticle content | Anticipated impact on Treg cells | Disease/conditions | NCT and phase |
|---|---|---|---|---|
Moderna | mRNA-6231: mRNA encoding IL-2 mutein | IL-2-mediated Treg cell expansion260 | Healthy volunteers | NCT04916431 (I) |
COUR (Takeda partnership for TAK-101) | TAK-101: gliadin | Nanoparticles release antigens in a tolerogenic manner, inducing Treg cells261 | Coeliac disease | NCT03486990 (I) and NCT03738475 (IIa) |
CNP-201: peanut protein | Peanut allergy | NCT05250856 (Ib/IIa) | ||
CNP-104: PDC-E2 | Primary biliary cholangitis | NCT05104853 (IIa) | ||
CNP-106: undisclosed antigen | Myasthenia gravis | NCT06106672 (Ib/IIa) | ||
Selecta Biosciences; now merged with Cartesian Therapeutics | ImmTOR: rapamycin; administered with non-encapsulated pegylated uricase | Creates tolerogenic environment; delivered antigen protected from antibody-mediated degradation131 | Gout | NCT02959918 (II) |
TOPAS Therapeutics | TPM502: major gluten epitopes | Antigen-conjugated nanoparticles targeted to the liver; antigen presentation is tolerogenic and induces Treg cells | Coeliac disease | NCT05660109 (II) |
TPM203: undisclosed antigen | Pemphigus vulgaris | EudraCT Number: 2019-001727-12 (I) |
